UnitedHealth Remarks 2

Conditions

Back to $390 = Second half of 2027 – early 2028
Probability: High (70%+), but must meet 4 core conditions

1. First, calculate: What $390 corresponds to

• Target: $390

• Corresponding reasonable P/E: 22x (upper limit of reasonable range)

• Required EPS: $390 ÷ 22 ≈ $17.73

2. Timeline (most likely path)

• Full year 2026: Bottom recovery period

◦ Target: MCR from 89.1% → 87.5–88.0%

◦ EPS: $17.75 (company guidance)

◦ Stock price: $300–$350 (P/E 17–20x)

• First half of 2027: Inflection point confirmation period

◦ MCR stabilizes at 86–87%, profit margin recovers to 5.5%+

◦ Valuation recovers to 19–21x

◦ Stock price: $350–$380

• Second half of 2027 – early 2028: Valuation + earnings double play

◦ MCR returns to 84–85% (healthy level)

◦ EPS revised up to **$18.5–$19.0**

◦ P/E returns to 21–22x

◦ Stock price: $390+

3. The 4 core conditions that must be met (all are essential)

1️⃣ MCR continuous improvement (most critical)

• 2026Q2: MCR <88.0% (quarter-on-quarter decline)

• Full year 2026: MCR ≤87.5%

• Full year 2027: MCR ≤85.0% (back to historical healthy range)

• Triggers: Premium increases, network optimization, cost control taking effect

2️⃣ Profit and margin recovery

• 2026: Operating profit margin from 4.2% → 5.5%+

• 2027: Profit margin returns to 6.0–6.5% (close to historical average)

• EPS: 2026≥$17.75; 2027≥$18.5; 2028≥$19.5

3️⃣ CMS policy and regulatory environment neutral

• Medicare Advantage (MA) payment policy does not worsen further

• V28 cost-cutting impact fully dissipates by 2027

• No new strong pricing/claim ratio pressure policies for healthcare

4️⃣ Valuation recovery + market sentiment improvement

• Healthcare sector valuation recovers from low levels to historical center

• Market shifts from "fearing MCR" to "recognizing leader's recovery capability"

• P/E from current 14.6x → 21–22x (upper limit of reasonable range)

4. Probability assessment

• High probability (70%+):

◦ Company proactively shrinks membership, optimizes network, raises premiums; MCR recovery path is clear

◦ Optum business is resilient, cash flow is stable, supporting recovery

◦ Buffett's holdings provide endorsement; long-term capital recognizes leader's value

• Risks (30%):

◦ Medical costs exceed expectations, MCR rebounds

◦ CMS further cuts MA payments

◦ High macro interest rates suppress defensive sector valuations

5. Key observation points (you can track)

• 2026Q2 earnings report (July): Whether MCR <88% (core inflection point signal)

• 2026Q4 earnings report (Jan 2027): Whether full-year MCR ≤87.5%

• 2027Q2 earnings report: Whether MCR <86%, profit margin >6%

Tracking

UnitedHealth stock price back to $390 target

Tracking condition checklist (concise and directly comparable)

1. Target corresponding valuation

• Target stock price: $390

• Corresponding P/E: 22x (upper limit of reasonable range)

• Corresponding EPS: ≥$17.75

• Path to achieve: EPS stabilizes + P/E recovers from 14.6x to 22x
2. Core conditions that must be met (all are essential)

1. Medical Cost Ratio (MCR) continuous improvement (most critical)

• Full year 2026 consolidated MCR: ≤ 87.5%

• Full year 2027 consolidated MCR: Falls back to 84.0%–85.0%

• MA business MCR: Falls back from 92% to ≤ 86%

• Observation signal: Quarterly MCR declines consecutively quarter-on-quarter, no rebound

1. Profit and margin return to healthy levels

• Full year 2026 EPS: ≥ $17.75 (meets company guidance)

• Net profit margin: Recovers from 2.7% to ≥ 5.0%

• Full year 2027 EPS: ≥ $18.50

• Free cash flow: ≥ $14.2 billion in 2026, continues to grow in 2027

1. CMS policy does not worsen

• 2027 CMS MA rate final rule: Not significantly below expectations

• Risk adjustment (V28) cost-cutting impact: Largely cleared by 2027

• No new harsh regulations, coding restrictions, or penalty policies targeting MA

1. External shocks and internal issues cleared

• Change Healthcare cyberattack impact completely eliminated

• DOJ-related investigations concluded, no massive fines or business bans

• Medical service utilization, medical inflation return to normal range

1. Valuation recovery conditions

• Market no longer assigns extreme pessimistic discount to healthcare stocks

• Institutional capital flows back, P/E recovers from current 14–15x
→ to 19–22x

• Broad market and interest rate environment stable, not suppressing defensive sector valuations
3. Timeline and corresponding stock price pace

Phase 1: 2026 Q2–Q3 (bottoming confirmation)

• Key observation: 2026 Q2 earnings report (July)

• Trigger signal: MCR < 88.0%

• Target stock price range: $280 – $320

Phase 2: End of 2026 – first half of 2027 (valuation recovery)

• Key observation: Full year 2026 earnings report + 2027 Q1 earnings report

• Trigger signal: Full-year MCR ≤ 87.5%, EPS meets target

• Target stock price range: $320 – $380

Phase 3: Second half of 2027 – early 2028 (reaching $390)

• Key observation: 2027 Q2–Q3 earnings reports

• Trigger signal: MCR stable at 84%–85%, EPS revised up

• Target stock price: $390+
4. One-sentence judgment

As long as MCR continues to decline and EPS stabilizes from 2026 to 2027, it is a high-probability event for UnitedHealth to reach $390 in the second half of 2027 to early 2028.